Reata Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Reata Pharmaceuticals

10/05/2022 14:31

* Reata Pharmaceuticals Inc  RETA.OQ  reported a quarterly
adjusted loss of $2.03​​ per share for the quarter ended in
March. The mean expectation of nine analysts for the quarter was
for a loss of $2.15 per share.
    * Revenue fell 3.2% to $914.00 thousand from a year ago; 
analysts
expected $1.55 million. 
    * Reata Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.03​.
    * The mean earnings estimate of analysts had risen by
about 3.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Reata Pharmaceuticals Inc shares had fallen by 36.8% this
quarter and lost 21.5% so far this year.
    * The company reported a quarterly loss of $73.84 million.
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $68.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 01:31 p.m.  ​All
figures in US dollars unless otherwise stated